<PAGE> 1
U. S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(MARK ONE)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2000
[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _________TO _________.
COMMISSION FILE NUMBER 000-21141
PHARMAPRINT INC.
(NAME OF SMALL BUSINESS ISSUER AS SPECIFIED IN ITS CHARTER)
DELAWARE 33-0640125
(STATE OR OTHER JURISDICTION OF (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION)
4701 VON KARMAN AVE SUITE 201,
NEWPORT BEACH, CALIFORNIA 92660
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANTS TELEPHONE NUMBER, INCLUDING AREA CODE: (949) 794-7778
Indicate by check mark whether the Registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the Issuer
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
Number of shares outstanding as of November 14, 2000: Common Stock: 20,905,767
<PAGE> 2
PHARMAPRINT INC. AND SUBSIDIARIES
INDEX
<TABLE>
<CAPTION>
Page
----
<S> <C>
Facing Sheet .................................................................... 1
Index ......................................................................... 2
PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Balance Sheets as of September 30, 2000
(unaudited) and March 31, 2000........................................... 3
Condensed Consolidated Statements of Operations for the three and six months
ended September 30, 2000 and 1999 (unaudited).................................... 4
Condensed Consolidated Statements of Cash Flows for the six months ended
September 30, 2000 and 1999 (unaudited) ......................................... 5
Notes to Condensed Consolidated Financial Statements (unaudited)................. 6
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations.................................................... 15
Item 3. Quantitative and Qualitative Disclosures About Market Risk............... 18
PART II. OTHER INFORMATION
Item 1. Legal Proceedings........................................................ 19
Item 2. Changes in Securities and Use of Proceeds................................ 20
Item 6. Exhibits and Reports on Form 8-K......................................... 21
Signatures ..................................................................... 22
</TABLE>
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This report contains "forward-looking" statements. The Company is
including this statement for the express purpose of availing itself of
protections of the safe harbor provided by the Private Securities Litigation
Reform Act of 1995 with respect to all such forward-looking statements. Examples
of forward-looking statements include, but are not limited to: (a) projections
of revenues, capital expenditures, growth, prospects, dividends, capital
structure and other financial matters; (b) statements of plans and objectives of
the Company or its management or Board of Directors; (c) statements of future
economic performance; (d) statements of assumptions underlying other statements
and statements about the Company and its business relating to the future; and
(e) any statements using the words "anticipate," "expect," "may," "project,"
"intend" or similar expressions.
The Company's ability to predict projected results or the effect of
certain events on the Company's operating results is inherently uncertain.
Therefore, the Company wishes to caution each reader of this report to carefully
consider the following factors and certain other factors discussed herein and in
the Company's Annual Report on Form 10-K for the fiscal year ended March 31,
2000 filed on August 17, 2000, any or all of which have in the past and could in
the future affect the ability of the Company to achieve its anticipated results
and could cause actual results to differ materially than those discussed herein:
cost and availability of botanical extracts, cost and availability of
manufacturing service contractors, ability to obtain and enforce patents,
limited manufacturing experience, dependence on third parties, uncertainties
related to the PharmaPrint(TM) Process, government regulation and uncertainty of
product approvals, ability to commercialize and market products, cost and
results of research and development and clinical and toxicology studies,
technological advances by third parties and competition, future capital needs of
the Company, control by existing shareholders and general economic and business
conditions.
PharmaPrint(TM) is a trademark of the Company
2
<PAGE> 3
PART I -- FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PHARMAPRINT INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
September 30, 2000 March 31, 2000
------------------ --------------
(Unaudited)
<S> <C> <C>
Assets
Current assets:
Cash and cash equivalents $ 427,636 $ 302,633
Accounts receivable, net of allowance for doubtful
accounts of $224,240 and $742,888 at September 30, 2000
and March 31, 2000, respectively -- --
Inventories 500,000 1,741,773
Other current assets 170,416 335,536
------------ ------------
Total current assets 1,098,052 2,379,942
Investment in joint venture 500,000 --
Property and equipment, net 146,308 200,000
------------ ------------
$ 1,744,360 $ 2,579,942
============ ============
Liabilities and stockholders' (deficit) equity
Current liabilities:
Accounts payable $ 14,168,259 $ 13,992,548
Accrued expenses 350,042 383,633
Short-term debt and current portion of long-term debt 120,587 77,611
------------ ------------
Total current liabilities 14,638,888 14,453,792
Long-term debt, net of current portion 96,201 137,352
------------ ------------
Total liabilities 14,735,089 14,591,144
------------ ------------
Stockholders' (deficit) equity:
Convertible Series A preferred stock, $0.001 par value - 1,000,000 shares
authorized, 7,005 and 7,110 shares issued and outstanding at September 30,
2000 and March 31, 2000, respectively (liquidation preference of $7,531,462
at September 30, 2000) 7 7
Common stock, $0.001 par value - 24,000,000 shares authorized, 20,905,767 and
16,830,425 shares issued and outstanding at September 30, 2000 and March 31,
2000,
respectively 20,906 16,831
Additional paid-in-capital 63,771,945 62,081,499
Deferred compensation (92,412) (101,903)
Accumulated deficit (76,691,175) (74,007,636)
------------ ------------
Total stockholders' (deficit) equity (12,990,729) (12,011,202)
------------ ------------
$ 1,744,360 $ 2,579,942
============ ============
</TABLE>
The accompanying notes are an integral part of
these condensed consolidated financial statements
3
<PAGE> 4
PHARMAPRINT INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
For the three months ended For the six months Ended
September 30, September 30,
-------------------------------- --------------------------------
2000 1999 2000 1999
------------ ------------ ------------ ------------
(Unaudited) (Unaudited)
<S> <C> <C> <C> <C>
Manufacturing revenues $ -- $ 589,774 $ 420 $ 5,999,392
Cost of sales 1,187,821 1,714,621 1,187,821 6,484,338
------------ ------------ ------------ ------------
Gross profit (loss) (1,187,821) (1,124,847) (1,187,401) (484,946)
------------ ------------ ------------ ------------
Operating expenses:
Research and development 3,755 3,198,937 36,211 5,343,659
General and administrative 1,153,654 2,159,376 2,140,140 3,736,632
Stock compensation 13,495 95,863 18,241 290,302
------------ ------------ ------------ ------------
Total operating expenses 1,170,904 5,454,176 2,194,592 9,370,593
Other income and expense:
Interest expense (81,222) -- (88,675) --
Gain on sale of non-marketable equity
securities -- -- 504,000 --
Other income 499,700 -- 499,700 --
Interest income 4,706 -- 6,701 --
------------ ------------ ------------ ------------
Total other income and expense 423,184 -- 921,726 --
------------ ------------ ------------ ------------
Net loss $ (1,935,541) $ (6,579,023) $ (2,460,267) $ (9,855,539)
============ ============ ============ ============
Net loss attributable to common stockholders:
Net loss $ (1,935,541) $ (6,579,023) $ (2,460,267) $ (9,855,539)
Less convertible preferred stock
dividend-in-kind (112,276) (151,233) (223,272) (193,973)
------------ ------------ ------------ ------------
Loss available to common stockholders $ (2,047,817) $ (6,730,256) $ (2,683,539) $(10,049,512)
============ ============ ============ ============
Net loss available to common stockholders
per share $ (0.11) $ (0.48) $ (0.15) $ (0.72)
============ ============ ============ ============
Basic/diluted weighted average common shares
outstanding 18,360,911 13,890,353 17,599,850 13,889,781
============ ============ ============ ============
</TABLE>
The accompanying notes are an integral part of
these condensed consolidated financial statements
4
<PAGE> 5
PHARMAPRINT INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
For The Six Months Ended
September 30,
------------------------------
2000 1999
----------- -----------
(Unaudited)
<S> <C> <C>
Cash flows from operating activities:
Net loss $(2,460,267) $(9,855,539)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation expense -- 130,466
Amortization expense -- 71,488
Stock compensation expense 18,241 290,302
Inventory write-downs 1,167,534 --
Amortization of debt discounts 67,500 --
Gain on sale of non-marketable equity securities (504,000) --
Changes in operating assets and liabilities:
Accounts receivable 221,000 2,157,117
Inventories 74,239 3,455,827
Other assets 165,120 (469,324)
Accounts payable and accrued expenses 162,497 (4,151,887)
----------- -----------
Net cash used in operating activities (1,088,136) (8,371,550)
----------- -----------
Cash flows from investing activities:
Investment in joint venture (500,000) --
Purchases of property and equipment -- (464,683)
Proceeds from the sale of fixed assets 53,692 --
Proceeds from sale of non-marketable equity securities 283,000 --
----------- -----------
Net cash used in investing activities (163,308) (464,683)
----------- -----------
Cash flows from financing activities:
Net proceeds from issuance of common stock and exercise
of stock options 1,394,999 --
Net proceeds from issuance of convertible preferred stock -- 9,935,361
Donated capital and net proceeds from exercise of
Common stock options -- 214,300
Repayment of short-term and long-term debt (18,552) (1,404,067)
----------- -----------
Net cash provided by financing activities 1,376,447 8,745,594
----------- -----------
Net change in cash and cash equivalents 125,003 (90,639)
Cash and cash equivalents, beginning of period 302,633 2,299,959
=========== ===========
Cash and cash equivalents, end of period $ 427,636 $ 2,209,320
=========== ===========
Supplemental disclosure of cash flow information:
Cash paid during the period for interest $ 13,889 $ 156,958
=========== ===========
</TABLE>
The accompanying notes are an integral part of
these condensed consolidated financial statements
5
<PAGE> 6
PHARMAPRINT INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
NOTE 1 - BASIS OF PRESENTATION
The financial statements of PharmaPrint, Inc. ("PharmaPrint" or the "Company")
for the three and six months ended September 30, 2000 and 1999 are unaudited.
Certain information and note disclosures normally included in the financial
statements prepared in accordance with generally accepted accounting principles
have been omitted. These financial statements should be read in conjunction with
the audited financial statements and notes thereto included in PharmaPrint's
Form 10-K as of and for the year ended March 31, 2000. In the opinion of
management, the financial statements contain all adjustments, consisting of
normal recurring adjustments, necessary to present fairly the financial position
of PharmaPrint for the periods presented. The interim operating results may not
be indicative of operating results for the full year or for any other interim
periods.
NOTE 2 - GOING CONCERN/RISK FACTORS
Risk Factors
Since inception (September 15, 1994) we have incurred significant losses
(totaling $76,691,175 through September 30, 2000) and has a working capital
deficit of $13,540,836 at September 30, 2000.
On October 21, 1999, we received a one-year termination notice regarding the
manufacture of certain products for AHP. From October 21, 1999 through November
15, 1999, we engaged in discussions with AHP to resolve certain issues between
the companies. On November 15, 1999, we were informed that, on November 8, 1999,
AHP initiated a legal action against us, alleging a number of claims including
breach of contract. AHP was seeking monetary damages, declaratory judgment and
injunctions. On November 16, 1999, we initiated an action against AHP, alleging
a number of claims including misappropriation of trade secrets, breach of
contract, violation of unfair competition laws and breach of the implied
covenant of good faith and fair dealing. We sought monetary damages, preliminary
and permanent injunctions, punitive damages, restitution and disgorgement and
other damages. On July 20, 2000, we entered into a confidential settlement
agreement with AHP that fully and finally resolved the actions of both parties.
We recorded the net impact of this settlement in other income for the three and
six month periods ended September 30, 2000.
We are currently negotiating settlement and payment arrangements with our
significant vendors that include both a reduction in the total amounts owed such
vendors and an extended payment plan should the vendors accept a reduced
payment. Certain vendors have also independently commenced legal actions against
us to collect amounts owed them and for various other damages (see Note 8). We
also intend to issue either common stock or warrants to purchase common stock to
the vendors as an incentive for the vendors to accept a reduced cash payment and
the extended payment plan. If we are
6
<PAGE> 7
PHARMAPRINT INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
unable to successfully negotiate arrangements with our vendors and/or are
unsuccessful in our defense of pending legal matters (see Note 8), we will
evaluate other options including, but not limited to, seeking protection from
the bankruptcy court. We have completed negotiations with several significant
vendors (see Note 7).
On May 4, 2000, we were de-listed from the NASDAQ National Market for failure to
maintain the net tangible asset requirement of NASDAQ, among other requirements.
The market price of our common stock is currently quoted on the NASD
Over-The-Counter Bulletin Board. The de-listing may make it more difficult for
us to raise capital in the public markets in the future.
At present, we are funding ongoing operations from cash on hand, from the
proceeds of the sale of our capital stock and from the proceeds of the sale of
non-marketable securities and fixed assets.
We continue to seek to raise additional equity and/or debt capital, sell our
technology or locate an appropriate merger candidate in order to pay current
liabilities, to fund current operations and to fund sales and marketing efforts
for new revenue distribution channels. Our ability to raise sufficient capital
and meet future capital requirements will depend on many factors, including but
not limited to: the outcome of stockholder and other litigation, our ability to
both reduce current amounts owed significant vendors and pay such amounts over
an extended time period, our ability to get our common stock re-listed on the
NASDAQ National Market or on a national securities exchange, our ability to
obtain new distribution channels to sell our products, cost and availability of
key botanical extracts, cost and availability of manufacturing service
contractors, ability to obtain and enforce patents, dependence on third parties
for collaboration/new distribution channels, and competition. Provided that we
can successfully raise capital and successfully negotiate settlement and payment
arrangements with significant vendors, we believe that our capital resources
will enable us to maintain reduced operations for the next six months. However,
no assurance can be given that additional capital, if needed, will be available
when required or upon acceptable terms or that we will be successful in our
efforts to negotiate with significant vendors.
The accompanying financial statements have been prepared on the basis of a going
concern, which contemplates the realization of assets and liquidation of
liabilities in the normal course of business. The financial statements do not
include any adjustments relating to the recoverability and classification of
asset carrying amounts (including the realizability of long-lived assets under
SFAS No. 121 and of inventories) or the amount and classification of liabilities
that might result from the outcome of this uncertainty.
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Revenue Recognition
Revenues are recognized when products are shipped to customers.
Other Income
Other income represents amounts received for transactions not directly related
to our revenue generating operations, including settlements from transactions
originating in prior periods.
7
<PAGE> 8
PHARMAPRINT INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Loss Per Share
PharmaPrint has adopted SFAS No. 128 "Earnings Per Share." As required pursuant
to SFAS No. 128, basic loss per share is computed based on the weighted average
number of common shares outstanding for the period. Diluted loss per share is
computed assuming dilution from stock options and warrants. All outstanding
stock options and warrants have been excluded from the diluted computation, as
their effect is antidilutive.
Comprehensive Income
PharmaPrint has adopted SFAS No. 130, "Reporting Comprehensive Income," which
established standards for the reporting and display of comprehensive income and
its components in financial statements. Comprehensive income generally
represents all changes in stockholders' equity except those resulting from
investments by and distributions to owners. There is no effect of SFAS No. 130
in these financial statements as we have no items of comprehensive income.
Segment Information
PharmaPrint has adopted SFAS No. 131, "Disclosures About Segments of an
Enterprise and Related Information," which established standards for the way
that public business enterprises report information about operating segments in
annual financial statements and requires that those enterprises report
information about operating segments in interim financial reports. SFAS No. 131
also establishes standards for related disclosures about products and services,
geographic areas and major customers. We believe that we currently operate under
one segment.
Recent Accounting Pronouncements
The FASB issued SFAS No. 133, "Accounting for Derivative Instruments and Hedging
Activities." SFAS 133 establishes accounting and reporting standards for
derivative instruments, including certain derivative instruments embedded in
other contracts, and for hedging activities. It requires that an entity
recognize all derivatives as either assets or liabilities on the balance sheet
at their fair value. This statement, as amended by SFAS 137, is effective for
financial statements for all fiscal quarters of all fiscal years beginning after
June 15, 2000. We do not expect the adoption of this standard to have a material
impact on results of operations, financial position or cash flows as we
currently do not engage in any derivative or hedging activities.
In March 2000, the Emerging Issues Task Force reached a consensus on Issue No.
00-2, "Accounting for Web Site Development Costs" ("EITF 00-2") to be applicable
to all web site development costs incurred for the quarter beginning after June
30, 2000. The consensus states that for specific web site development costs, the
accounting for such costs should be accounted for under AICPA Statement of
Position 98-1 (SOP 98-1), "Accounting for the Costs of Computer Software
Developed or Obtained for
8
<PAGE> 9
PHARMAPRINT INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Internal Use." We do not expect the adoption of EITF 00-2 to have a material
effect on our financial statements.
In March 2000, the FASB issued Interpretation No. 44 ("FIN 44"), "Accounting for
Certain Transactions involving Stock Compensation," an interpretation of APB 25.
FIN 44 clarifies the application of APB 25 for (a) the definition of employee
for purposes of applying APB 25, (b) the criteria for determining whether a plan
qualifies as a noncompensatory plan, (c) the accounting consequence for various
modifications to the terms of a previously fixed stock option or award, and (d)
the accounting for an exchange of stock compensation awards in a business
combination. FIN 44 is effective July 1, 2000, but certain provisions cover
specific events that occur after either December 15, 1998, or January 12, 2000.
The adoption of certain other provisions of FIN 44 prior to March 31, 2000 did
not have a material effect on the financial statements. We do not expect that
the adoption of the remaining provisions will have a material effect on the
financial statements.
In December 1999, the Securities and Exchange Commission issued Staff Accounting
Bulletin 101 ("SAB 101"), "Revenue Recognition," which outlines the basic
criteria that must be met to recognize revenue and provides guidance for
presentation of revenue and for disclosure related to revenue recognition
policies in financial statements filed with the Securities and Exchange
Commission. The effective date of this pronouncement is the fourth quarter of
the fiscal year beginning after December 15, 1999. We believe that adopting SAB
101 will not have a material impact on our financial position and results of
operations.
NOTE 4 - INVENTORIES
During the quarter ended September 30, 2000, management wrote down the value of
inventories to $500,000, based on management's best estimate of the net
realizable value of these inventories. Related to this write-down, we incurred a
non-cash expense of $1,167,534 that is included in the cost of sales for the
quarter then ended.
NOTE 5 - NON-MARKETABLE EQUITY SECURITIES
Non-marketable equity securities consist of shares of Vicus.com, Inc. ("Vicus").
Vicus was formed by PharmaPrint and several related parties, and was for some
time operating out of our offices. During the first quarter of fiscal 2001, we
sold our remaining 420,000 shares at $1.20 per share to unrelated parties, of
which $221,000 has not yet been collected and has been fully reserved for in the
accompanying condensed balance sheet as the collection of this amount is
doubtful. The proceeds of $504,000 from the sales of this stock are recorded as
a gain on the sale of non-marketable equity securities as the stock's net book
value was $0.
NOTE 6 - AGREEMENTS
As part of a Settlement Agreement with AHP dated July 20, 2000, all agreements
with AHP have been terminated (see Note 1).
9
<PAGE> 10
PHARMAPRINT INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
USC License Agreement
In March 1995, we entered into a license agreement with USC (the "USC License
Agreement") that granted to us an exclusive, worldwide license to: (i) the
PharmaPrint(TM) Process; (ii) use certain therapeutic compounds; and (iii) other
related products developed at USC. USC has also agreed to grant to us the right
to sublicense certain products and a right of first refusal to obtain a license
for any improvements to certain products developed by USC. The term of the USC
License Agreement began March 1, 1995, and ends on the later of February 28,
2010, or the expiration of the last issued patent under the USC License
Agreement.
In exchange for the license, we agreed to pay USC: (i) royalty payments of 1% of
net sales of pharmaceutical products developed using the PharmaPrint(TM)
Process; (ii) after the first patent issues, an annual minimum royalty of
$15,000, which shall increase by $5,000 annually for the following two years and
be $25,000 annually thereafter; (iii) an annual license fee of $10,000 payable
until a patent issues; and (iv) 328,563 shares of our common stock valued at
$316,000 at the time of the exchange.
Total minimum royalty expense per year under the USC License Agreement is
$25,000. As of September 30, 2000, we have remitted the royalty payment
according to the terms of the USC License Agreement. We were previously in
default of this agreement.
Joint Venture
In August 2000, we entered into a joint venture agreement with Capital Alert
Investment Ltd. (a British Virgin Islands Company) for the purpose of
establishing Kingsway PharmaPrint Asia Limited, A British Virgin Islands Company
("Kingsway PharmaPrint"). The agreement includes a Joint Venture Shareholders'
Agreement, a License and Distribution Agreement and a Share Subscription
Agreement. We own 30% of Kingsway PharmaPrint's issued and outstanding equity
securities.
The Joint Venture Shareholders' Agreement between PharmaPrint Inc. and Capital
Alert Investment Ltd. established Kingsway PharmaPrint Asia Limited, a British
Virgin Islands company. The company's purpose is to manufacture, distribute and
market products (other than pharmaceutical products) in Asia and Pacific
territory using the PharmaPrint(TM)Process. Under this agreement, we provided an
initial investment of $500,000 and technology (PharmaPrint(TM)Process) while
Capital Alert Investment Ltd. will provide office space and marketing ability in
the Asia and Pacific territory. In addition, Capital Alert Investment Ltd. is
entitled to appoint two members of our Board of Directors. Kingsway PharmaPrint
had no activity as of September 30, 2000.
Under the License and Distribution Agreement, we provide a license to Kingsway
PharmaPrint to manufacture, market and distribute PharmaPrint products (other
than pharmaceutical products) made using the PharmaPrint(TM) Process in Asia and
Pacific territory. In exchange, we will receive royalties of 5% on gross sales
of products.
10
<PAGE> 11
PHARMAPRINT INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
In the Share Subscription Agreement between PharmaPrint Inc. and Capital Alert
Investment Ltd. ("Capital"), Capital purchased 3,750,000 shares of common stock
for the amount of $1,500,000. We used $500,000 of the proceeds from the sale of
this common stock to fund our initial investment in the joint venture. Capital
has a five-year option to acquire an additional 2,500,000 shares of common stock
at exercise prices ranging from $0.375 to $1.25 per share. Additionally, one of
Capital Alert Investment, Ltd.'s appointees to our Board of Directors was
granted a five-year option to purchase 150,000 shares of common stock at an
exercise price of $0.375 per share. Pursuant to APB 25 we did not recognize any
expense related to the granting of these options since the exercise price of
these options was greater than the market value of our common stock on the date
of grant.
First Pacific Consulting Group
In relation to the joint venture, we entered into a Compensation Agreement with
First Pacific Consulting Group, Inc. of Oklahoma ("First Pacific"). For services
provided in brokering the joint venture transactions. First Pacific is entitled
to a 7% commission on monies received from Capital (totaling $105,000, that has
already been paid). In addition, First Pacific received a three-year option to
purchase 500,000 shares of our common stock at a price of $0.375 per share.
First Pacific is not permitted to resell the common stock underlying this option
into the public market for a period of six months from the date of this option.
As the stock option was granted in connection with capital raising activities,
we did not record any compensation expense and accounted for this option
pursuant to SFAS 123.
If and when Capital Alert Investment Ltd. exercises its option to purchase
PharmaPrint Inc. shares of common stock, pursuant to the Share Subscription
Agreement, First Pacific will then be entitled to a 7% commission of such
exercise cost.
Diabetogen
On October 2, 2000, we entered into a License Agreement with Diabetogen
Biosciences Inc. ("Diabetogen") of Ontario, Canada. The agreement grants to
Diabetogen an exclusive worldwide right to claims 1-10 of US Patent 5,547,674
and allows Diabetogen the rights to develop, produce and sell licensed products.
In exchange we will receive annual maintenance fees, milestone payments for
entry into clinical trials and royalties on net sales of licensed products.
NOTE 7 - VENDOR NEGOTIATIONS
Accounts Payable Settlements
We are currently negotiating settlement and payment arrangements with our
significant vendors that include both a reduction in the total amounts owed such
vendors and an extended payment plan should the vendors accept a reduced
payment. Certain vendors have also independently commenced legal actions against
us to collect amounts owed them and for various other damages. We also intend to
issue either common stock or warrants to purchase common stock to the vendors as
an incentive for the vendors to accept a reduced cash payment and the extended
payment plan. If we are unable to successfully negotiate arrangements with our
vendors and/or are unsuccessful in our defense of pending legal matters, we will
evaluate other options including, but not limited to, seeking protection from
the bankruptcy court.
11
<PAGE> 12
PHARMAPRINT INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
We have obtained settlement agreements with certain of our vendors. The
settlement agreements require us to issue non-interest bearing notes with
payments totaling one-half of the amount owed to each of the vendors.
Additionally, we will transfer 1,000,000 shares of our common stock to these
settling creditors on a pro-rata basis. The agreements are contingent on each of
the settling creditors signing the agreements; otherwise, all of the agreements
will be null and void. If all of these agreements are signed, we will reduce our
obligations in exchange for stock, which may produce a potential extraordinary
gain on extinguishment of debt.
During the current fiscal year Pennie and Edmonds, LLP ("PEL"), filed a
lawsuit against us for unpaid legal fees in the amount of $225,000. We contend
that PEL's estimation of the fees owed to them is based upon excessive and
inappropriate charges for services that are unjustified. On October 20, 2000,
the parties reached an amicable settlement of this matter.
NOTE 8 - PENDING LITIGATION
In July 1999 Applied Analytical Industries, Inc. ("AAI"), a vendor, filed a
Demand for Arbitration with the American Arbitration Society, seeking to recover
damages for alleged breach of contract related to a Manufacturing Contract. In
December 1999 we initiated a counterclaim against AAI. We filed the suit for
claims arising from breach of contract, fraudulent inducement and fraud and
negligence arising from various manufacturing and analytical agreements between
the companies. We are seeking in excess of $6,000,000 in damages, and AAI is
seeking in excess of $6,000,000 for payment of unpaid charges, interest and
other damages. In August of 2000, we reached a settlement with AAI, agreeing to
issue 2.2 million shares of our common stock in exchange for the relief of
approximately $5.5 million in accounts payable and a mutual dismissal of all
actions. The parties plan to consummate this settlement during the third quarter
of fiscal year 2001. We will not recognize a gain on this legal settlement
unless we avoid an "Act of Bankruptcy", as defined in the settlement agreement,
for a period of 270 days after the date we issue the shares to AAI.
On February 3, 2000, we were served with a class action complaint filed January
5, 2000, as amended January 27, 2000. This action is purportedly on behalf of
all persons who acquired the common stock of PharmaPrint between July 1, 1999
and November 15, 1999. We were also served with a separate class action
complaint filed January 20, 2000. These actions were purportedly filed on behalf
of all persons who purchased the common stock of PharmaPrint from April 1, 1999
through November 17, 1999. The plaintiffs are seeking compensatory damages, and
other costs and expenses, including legal fees. These two matters were recently
consolidated before the Honorable Judge John W. Bissell in the Federal District
Court of New Jersey, Newark, enabling more efficient resolution of the dispute.
No class has been certified. Our officers and we intend to vigorously defend the
merits of the lawsuits.
On March 31, 2000 we settled a suit with International Processing Corporation
("IPC"), a vendor. In the settlement, we agreed to issue a promissory note which
called for quarterly payments of $25,000 beginning on June 30, 2000, with a
balloon payment of $75,000 due on March 30, 2002 and a pro-rata percentage of
1,000,000 shares (as determined by a percentage of the total amount of debt
released by IPC over the total amount released by all other vendors - see Note
7) in exchange for a release from all amounts due to IPC prior to the agreement.
We discounted the note using a 12% interest rate, and transferred the present
value of the payment obligations of $20,376, from accounts payable to notes
payable. No gain on extinguishment of debt will be recognized until the number
of shares is determined.
12
<PAGE> 13
PHARMAPRINT INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
On March 29, 2000 we were informed that an action was filed by former employee
Kenneth Gorelick alleging damages arising out of employment with PharmaPrint in
excess of $150,000 plus interest and costs. We contend that this is not a
legitimate claim. We believe that we have meritorious defenses to these claims
and intend to vigorously defend this lawsuit. As the outcome and final amount we
will be required to pay the plaintiff, if any, are not determinable, no accrual
for loss relating to this lawsuit is reflected in the accompanying financial
statements.
In April 2000, we initiated an action against Bio Dar, Inc. ("Bio Dar"), a
vendor. We filed the suit for claims arising from establishment of rights and to
verify ownership of intellectual properties. We are seeking $2.5 million in
damages. Bio Dar has filed an answer to the suit, and has initiated a counter
suit for damages not exceeding the amount sought by us. In August 2000, Bio Dar
filed another lawsuit against us seeking payment of outstanding invoices
totaling approximately $165,000. We believe that we have meritorious defenses to
these claims and intend to vigorously defend these lawsuits. As the outcome and
final amounts are not determinable, no accrual for loss relating to this suit is
reflected in the accompanying financial statements.
NOTE 9 - STOCKHOLDERS' EQUITY
Convertible Series A Preferred Stock
The Series A Preferred Stock has a dividend yield of 6%, payable at the time of
conversion in shares of our common stock. For the six months ended September 30,
2000, we recorded dividends-in-kind of $223,272 related to preferred stock
dividends that will be due upon conversion. Because this dividend amount will
not be paid in cash, it is shown as a decrease in the accumulated deficit
account and a corresponding increase in the additional paid in capital account
in the accompanying consolidated balance sheet. This amount has also been
disclosed as an increase to the preferred stock's liquidation preference at
September 30, 2000.
On July 5, 2000, 105 shares of preferred stock and related accrued dividends
were converted into 325,342 shares of common stock.
Options Granted
On April 14, 1995, the Company adopted the 1995 Stock Option Plan, as amended,
(the "Plan") pursuant to which our directors, officers, key employees,
consultants, scientific advisors and other personnel working directly with us
are eligible to receive stock options as defined in the 1995 Plan. 5,900,000
shares of common stock were authorized for issuance under the 1995 Plan. The
1995 Plan, unless terminated sooner by the Board of Directors, will terminate on
April 14, 2005.
13
<PAGE> 14
PHARMAPRINT INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
On May 15, 2000, we granted to Steven Bowman, Chief Executive Officer,
non-qualified stock options to purchase 500,000 shares of common stock at the
then fair market value of $0.375 per share. Mr. Bowman's right to purchase
125,000 shares of common stock will vest on each of August 15, 2000, November
15, 2000, February 15, 2001 and May 15, 2001. Additionally, Mr. Bowman's right
to purchase shares of common stock will vest upon a change in control of
ownership of our company or upon his achieving certain specified goals as
defined in the agreement between us and Mr. Bowman.
On August 1, 2000, we granted to an outside consultant for services, options to
purchase 25,000 shares of common stock at an exercise price of $0.375. We
recorded, pursuant to SFAS 123, a consulting expense of $8,750.
On August 31, 2000, we granted to Capital Alert Ltd. a five-year option to
purchase 2,500,000 shares of common stock at the following exercise prices per
share: 500,000 at $0.375; 500,000 at $0.45; 1,000,000 at $1.00; and 500,000 at
$1.25.
(Note 6)
Also on August 31, 2000, we granted to a new board member a five-year option to
purchase 150,000 shares of common stock at an exercise price of $0.375 per share
(Note 6). Pursuant to FIN 44 we did not record any compensation expense related
to the granting of these options due to the fact that the grant price was
greater than the market value of our common stock on the date of grant.
On September 6, 2000, we granted to First Pacific Consulting Group, Inc. a
three-year option to purchase 500,000 shares of common stock at an exercise
price of $0.375 per share. (Note 6)
NOTE 10 - LINE OF CREDIT
On May 8, 2000, we entered into a line of credit agreement with Montecito
Leasing Group, LLC ("Montecito"). Pursuant to the terms of the agreement, we
obtained a $1,000,000 credit line with a maturity date of November 22, 2000.
Outstanding borrowings under this line bear interest at 10% per annum payable
monthly and are secured by substantially all of our assets including all of our
inventories, fixed assets, patents and pending patents. At September 30, 2000,
the balance on this line was $0.
Concurrent with the line of credit, we granted Montecito a warrant to purchase
500,000 shares of common stock at an exercise price of $0.40 per share. 250,000
of these shares are exercisable immediately, with the other 250,000 shares
exercisable when and if we have borrowed an aggregate of $1,000,000 under the
line of credit. The warrant agreement also contains a cashless exercise option,
registration rights and anti-dilution provisions as more fully described in the
warrant agreement. The warrant expires in May 2005. The fair value of the
exercisable portion of this warrant of $67,500 was recorded as a debt discount
and has been fully amortized in the three months ended September 30, 2000, since
the line of credit has been paid in full.
14
<PAGE> 15
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
OVERVIEW
We intend to use our PharmaPrint(TM) Process technology to develop high quality
dietary supplement, functional food and pharmaceutical products from botanical
sources. We believe that our PharmaPrint(TM) Process Technology represents a new
paradigm in the development of therapeutic products from botanical sources.
Unlike the traditional drug development process of identifying, isolating and
synthesizing single bioactive molecules from plant and other sources, our core
technologies were developed based on empirical data suggesting that the health
benefits and safe usage of certain plant-derived therapeutics might be the
result of the natural combination of multiple molecules found in the plant
extract and that single molecules, in isolation, may not replicate the natural
plant's effectiveness. The PharmaPrint(TM) Process technology enables us to
identify, quantify and standardize the bioactives within plant sources that are
believed to provide therapeutic benefits and produce products having consistent
batch-to-batch quantities of these bioactives.
We intend to commercialize development efforts for four distinct product lines
derived from botanical sources: 1) single herbal dietary supplement products; 2)
herbal dietary supplements in combination with vitamins and minerals; 3) FDA
approved pharmaceuticals from plant sources and 4) functional food products
based on soy or soy dietary supplements.
In September 1999, we launched six combination products that were initially
marketed on three websites.
In the summer of 1999, we completed analysis of the Phase II study for our
initial pharmaceutical product candidate, PPRT-321, a saw palmetto-derived drug
that is being developed for the treatment of symptoms associated with BPH. The
clinical study data demonstrated that the product was safe and appeared to
improve symptoms associated with an enlarged prostate gland. We are currently
devoting limited resources to our pharmaceutical program to maintain an active
Saw-Palmetto Investigational New Drug Application.
In the spring of 1999, we began using the PharmaPrint(TM) Process technology on
soy, a product classified as both a functional food and dietary supplement.
Initial results of this work were submitted in a provisional patent application.
RESULTS OF OPERATIONS - THREE MONTHS ENDED SEPTEMBER 30, 2000
American Home Products Corporation ("AHP") accounted for substantially all sales
for the three months ended September 30, 1999. The relationship with this
customer was terminated during fiscal year 2000 due to significant litigation
between the two parties as described below. As a result, we have no current
distribution channels to market our products and have essentially ceased all
revenue-generating activities. No manufacturing revenues were realized for the
three months ended September 30, 2000 compared to $589,774 for the three months
ended September 30, 1999. Costs of sales expense for the three months ended
September 30, 2000 were $1,187,821 compared to $1,714,621 realized for the three
months ended September 30, 1999. Costs of sales incurred during the current
quarter are primarily attributable to a write-down in inventory.
15
<PAGE> 16
Research and development expenses for the three months ended September 30, 2000
were $3,755 compared to $3,198,937 for the three months ended September 30,
1999. Prior to the AHP agreement, we engaged primarily in research and
development activities and reported as a development stage company. During the
term of the AHP agreement, we continued research and development activities, but
due to lack of revenue and the resulting shortage of funds, we have suspended
such activities.
In the course of business, general and administrative expenses were incurred
necessary for on-going operations. In our current financial condition, senior
management made such attempts as reasonable to reduce these expenses. Such
expenses were $1,153,654 for the three months ended September 30, 2000, a
$1,005,722 or 47% decrease compared to $2,159,376 for the three months ended
September 30, 1999. Major components of the general and administrative expenses
incurred for the three months ended September 30, 2000 include: legal fees of
$290,543; bad debt expense of $222,298; wages and benefits of $217,830;
consulting fees of $85,719; insurance of $79,807; equipment lease obligations of
$72,584; and accounting and audit fees of $60,234.
Stock compensation was $13,495 for the three months ended September 30, 2000
compared to $95,863 for the three months ended September 30, 1999. The decrease
is due to less options and a lower valuation of options and warrants granted in
the current period.
Other income in the amount of $499,700 was recognized during the three months
ended September 30, 2000 consisting of legal and vendor settlements. There was
no such income during the three months ended September 30, 1999.
As a result of the above factors, net loss for the three months ended September
30, 2000 was $1,935,541, a decrease of $4,643,482 or 71% compared to $6,579,023
for the three months ended September 30, 1999. Net loss per share available to
common stockholders was eleven cents for the three months ended September 30,
2000 compared to a net loss per common share of forty-eight cents for the three
months ended September 30, 1999.
RESULTS OF OPERATIONS - SIX MONTHS ENDED SEPTEMBER 30, 2000
Manufacturing revenues of only $420 were realized for the six months ended
September 30, 2000 compared to $5,999,392 for the six months ended September 30,
1999. Sales during the six months ended September 30, 1999 were primarily
attributable to AHP. Costs of sales expense for the six months ended September
30, 2000 was $1,187,821 compared to $6,484,338 realized for the six months ended
September 30, 1999. Costs of sales incurred for the current period were
primarily attributable to a write-down in inventory.
Research and development expenses for the six months ended September 30, 2000
were $36,211 compared to $5,343,659 for the six months ended September 30, 1999.
The decrease in research and development expenses is due to the suspension of
these activities as previously stated.
General and administrative expenses were incurred necessary for our continued
operation. In our current financial condition, senior management made such
attempts as reasonable to reduce these expenses. Such expenses were $2,140,140
for the six months ended September 30, 2000, a $1,596,492 or 43% decrease
compared to $3,736,632 for the six months ended September 30, 1999. Major
components of the general and administrative expenses incurred for the six
months ended September 30, 2000 include: wages and benefits of $498,839:
equipment lease obligations of $358,994; legal fees of $357,311; bad debt
expense of $222,298; consulting fees of $115,749; insurance of $107,649;
accounting and audit fees of $106,272; and office lease of $103,478.
16
<PAGE> 17
Stock compensation was $18,241 for the six-months ended September 30, 2000
compared to $290,302 for the six-months ended September 30, 1999. This decrease
is due to less options and a lower valuation of options and warrants granted to
consultants in fiscal year 2000.
We recorded a gain on sale of non-marketable equity securities of $504,000
during the six months ended September 30, 2000. There were no such sales in the
comparable period of 1999.
Other income in the amount of $499,700 was recognized during the six months
ended September 30, 2000 consisting of legal and vendor settlements. There was
no such income during the six months ended September 30, 1999.
As a result of the above factors, net loss for the six months ended September
30, 2000 was $2,460,267, a decrease of $7,395,272 or 75% compared to $9,855,539
for the six months ended September 30, 1999. Net loss per share available to
common stockholders was fifteen cents for the six months ended September 30,
2000 compared to a net loss per common share of seventy-two cents for the six
months ended September 30, 1999.
CHANGES IN FINANCIAL POSITION, LIQUIDITY AND CAPITAL RESOURCES
During the six months ended September 30, 2000 we sold common stock for proceeds
of $1,395,000 (net of commissions of $105,000), invested $500,000 in a joint
venture, sold non-marketable equity securities for proceeds of $283,000 and sold
fixed assets for proceeds of $53,692. These transactions partially offset cash
used in operating activities of $1,088,136. Cash and cash equivalents increased
$125,003 for the six months ended September 30, 2000 and were $427,636 at
September 30, 2000. For the six months ended September 30, 1999, we realized net
proceeds of $9,935,361 from issuance of redeemable preferred stock. The proceeds
from issued preferred stock were partially offset by net cash used in operating
activities of $8,371,550. For the six months ended September 30, 1999, cash and
cash equivalents decreased $90,639 and were $2,209,320 at September 30, 1999.
We currently have a negative working capital position and intend to rely on
proceeds from a recent capital investment and sales of inventory and available
machinery to pay day-to-day expenses. We also have a loan that allows us to
borrow up to $500,000 under certain circumstances. It may increase to $1,000,000
under certain conditions. As of September 30, 2000, we have borrowed and repaid
$418,000 of the $500,000 available to us. The lender has a security interest on
substantially all of our assets securing the repayment of all amounts advanced
to us under this line of credit. The lender has rights that effectively allow it
to direct how we spend any loan proceeds that we receive and to withhold the
advance of funds pursuant to this line of credit for any reason or for no reason
at all.
Our Independent Auditors' qualified their opinion and expressed doubt about our
ability to continue as a going concern for the consolidated balance sheets as of
March 31, 2000 and the results of operations and cash flows for the year ended
March 31, 2000. They stated that "the ability of the Company to continue in
existence is dependent primarily upon negotiating acceptable settlement and
payment terms with its significant vendors, obtaining additional debt and equity
financing to fund its short-term operating expenses and to fund sales and
marketing efforts for new revenue channels of distribution, successful
resolution of its customer, vendor and stockholder litigation, as well as the
generating of income form collaborative relationships, new partners and other
new revenue distribution channels."
On May 4, 2000, we were de-listed from the NASDAQ National Market for failure to
maintain the net tangible asset requirement of NASDAQ, among other requirements.
The market price of our common stock is currently quoted on the NASD
Over-The-Counter Bulletin Board. The de-listing may make it more difficult for
us to raise capital in the public markets in the future.
17
<PAGE> 18
As of September 30, 2000 7,005 shares of our Series A were issued and
outstanding. The Series A Preferred Stock has a dividend rate of six percent,
payable at the time of conversion in shares of our common stock. Upon the
occurrence of certain liquidation events, the holders of our Series A Preferred
Stock are entitled to receive, in preference over the holders of common stock
and any preferred stock ranking junior to our Series A Preferred Stock, an
amount equal to the stated value plus 6% per year (pro rated for any partial
year) of such stated value beginning on June 4, 1999 and ending on the date of
final distribution. Our Series A Preferred Stock is also redeemable at the
option of the holder if at the time of conversion we fail to issue shares of our
common stock to the holders of Preferred Stock or if the registration statement
registering the resale of the common stock issuable upon conversion of the
Series A Preferred Stock is not effective for specified periods.
As discussed in Note 7 to our Condensed Consolidated Financial Statements on
page 11 of this report we are currently negotiating settlement and payment
arrangements with our significant creditors. If we are unsuccessful in creating
these arrangements then we will evaluate other options including, but not
limited to, seeking protection from the bankruptcy court.
We continue to seek to raise additional equity and/or debt capital, sell our
technology or locate an appropriate merger candidate in order to pay our current
liabilities, to fund current operations and to fund sales and marketing efforts
for new revenue distribution channels. Our ability to raise sufficient capital
and meet future capital requirements will depend on many factors, including but
not limited to: the outcome of stockholder and other litigation, our ability to
both reduce current amounts owed to significant vendors and pay such amounts
over an extended time period, our ability to get our common stock re-listed on
the NASDAQ National Market or on a national securities exchange, our ability to
obtain new distribution channels to sell its products, cost and availability of
key botanical extracts, cost and availability of manufacturing service
contractors, ability to obtain and enforce patents, dependence on third parties
for collaboration/new distribution channels, and competition. Provided that we
can successfully raise capital and successfully negotiate settlement and payment
arrangements with significant vendors, we believe that our capital resources
will enable us to maintain reduced operations for the next six months. However,
no assurance can be given that sufficient capital exists for reduced operations
and that additional capital, if needed, will be available when required or upon
terms acceptable to us or that we will be successful in our efforts to negotiate
with significant vendors.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are not currently directly exposed to market risks related to
fluctuations in interest rates in long-term or short-term debt. Currently, and
as of September 30, 2000, we have no variable interest rate loans.
However, if interest rates do increase from their current levels, we may
have more difficulty in obtaining debt financing than we might otherwise, and if
we are successful, then the terms under which we would be able to obtain
financing would be less favorable to us.
18
<PAGE> 19
PART II -- OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
On November 16, 1999, we initiated an action against American Home
Products Corporation ("AHP") in the Orange County, California Superior Court
alleging a number of claims including misappropriation of trade secrets, breach
of contract, and violation of fair dealing. On November 8, 1999, American Home
Products Corporation initiated an action against us in the Superior Court of New
Jersey, Morris County Law Division alleging a number of claims including breach
of contract. On July 20, 2000, we settled with American Home Products
Corporation and all actions were dismissed.
During the current fiscal year Pennie and Edmonds, LLP ("PEL"), filed a
lawsuit against us for unpaid legal fees in the amount of $225,000. We contend
that PEL's estimation of the fees owed to them is based upon excessive and
inappropriate charges for services that are unjustified. On October 20, 2000,
the parties reached an amicable settlement of this matter.
On August 31, 2000, we entered into a Settlement Agreement with Applied
Analytical Industries, Inc. ("AAI") pursuant to which the parties settled their
respective claims that are the subject of a judicial proceeding in the New
Hanover County Superior Court in the state of North Carolina and a separate
arbitration proceeding. Pursuant to the Settlement Agreement, the parties
agreed:
o to file dismissals of each of the aforementioned legal
proceeding and arbitration proceeding with prejudice;
o to execute a mutual release;
o that we would issue 2,200,000 shares of our common stock to
AAI in settlement and in exchange for AAI's release of certain
specific claims raised in the legal proceeding and arbitration
proceeding by AAI which total an aggregate of approximately
$5.5 million (the "AAI Claims").
These shares of common stock are "restricted stock" as that term is
defined under Rule 144 promulgated under the Securities Act of 1933, as amended
(the "Securities Act") and may only be resold following AAI's delivery to us of
an opinion of legal counsel to the effect that a public sale or transfer of such
shares may be made without registration under the Securities Act and is in
compliance with all applicable federal and state rules and regulations. If,
within 270 days following receipt by AAI of our common stock issued in exchange
for its release of the AAI Claims, we have an "Act of Bankruptcy" (as defined in
the Settlement Agreement), then:
o we will be required to reacquire all shares of our common
stock which are still owned by AAI as of the date of such Act
of Bankruptcy at a per share cash price of $1.37; and
o AAI's release of the AAI Claims shall become null and void
with respect to an amount equal to $3 million less the amount
of any payments which we make to AAI to reacquire our shares
of common stock and the gross proceeds received by AAI from
its sale of the shares of our common stock through the date of
such Act of Bankruptcy.
The parties plan to consummate the terms of this settlement agreement
during the third quarter of fiscal year 2001.
19
<PAGE> 20
On August 18, 2000, Julien J. Studley, Inc. filed an action against us
in the Superior Court of California, County of Los Angeles, alleging breach of
contract in relation to the termination of our previous office lease with
Spieker Properties, L.P.. The complaint seeks damages in the amount of
$35,930.95. We believe we have a meritorious defense to this claim and intend to
vigorously defend this lawsuit.
On October 13, 2000, IOS Capital, Inc. filed an action against us in
the Superior Court of the State of California, County or Orange, alleging breach
of contract in relation to office equipment leases. The complaint seeks damages
in the amount of $71,512.20. We are still in process of evaluating this claim
and believe we have defenses against this allegation.
ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS
In August 2000, in connection with a joint venture agreement, we sold
3,750,000 shares of our common stock to Capital Alert Investment, Ltd. for an
aggregate purchase price of $1,500,000. We also issued Capital Alert Investment,
Ltd. options to purchase shares or our common stock, as follows:
Number of Options Exercise Price Per Share
------------------ ------------------------
500,000 $0.375
500,000 $0.45
1,000,000 $1.00
500,000 $1.25
In connection with this joint venture agreement, we also issued options to
purchase 150,000 shares of our common stock at an exercise price of $0.375 per
share to Hardy Chan, Capital Alert Investment Ltd.'s appointee to our Board of
Directors. Each of these options expires five years from their grant date. For
services provided in brokering the joint venture transaction, we issued First
Pacific Consulting Group, Inc. of Oklahoma an option to purchase 500,000 shares
of our common stock at an exercise price of $0.375 per share. This option
expires three years from its grant date. We issued all of these securities
pursuant to Section 4(2) of the Securities Act of 1933, as amended.
20
<PAGE> 21
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) The following exhibits are included herein:
10.16 Settlement Agreement by and between Applied Analytical Industries, Inc.
and PharmaPrint, Inc. dated as of August 31, 2000.
10.17 Joint Venture Shareholders' Agreement by and between PharmaPrint, Inc.
and Capital Alert Investment, Ltd. dated August 31, 2000.
10.18 License and Distribution Agreement by and between PharmaPrint, Inc. and
Kingsway PharmaPrint Asia Limited dated August 31, 2000.
10.19 Share Subscription Agreement by and between PharmaPrint, Inc. and
Capital Alert Investments, Ltd. dated August 31, 2000.
27.1 Financial Data Schedule
(b) We did not file any reports on Form 8-K during the fiscal quarter ended
September 30, 2000.
21
<PAGE> 22
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
PHARMAPRINT INC.
By: /s/ Steven A. Bowman
--------------------------------------
Steven A. Bowman
Chief Executive Officer, Principal
Accounting Officer
Date: November 20, 2000
22
<PAGE> 23
EXHIBIT INDEX
Exhibit Number Description
-------------- -----------
10.16 Settlement Agreement by and between Applied Analytical
Industries, Inc. and PharmaPrint, Inc. dated as of August 31,
2000.
10.17 Joint Venture Shareholders' Agreement by and between
PharmaPrint, Inc. and Capital Alert Investment, Ltd. dated
August 31, 2000.
10.18 License and Distribution Agreement by and between
PharmaPrint, Inc. and Kingsway PharmaPrint Asia Limited dated
August 31, 2000.
10.19 Share Subscription Agreement by and between PharmaPrint, Inc.
and Capital Alert Investments, Ltd. dated August 31, 2000.
27.1 Financial Data Schedule
23
